Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC

This is a Phase I, open-label, multi-center study to assess the safety, pharmacokinetics, and preliminary efficacy of GPC3-directed chimeric antigen receptor modified T cells injection (Ori-C101) in Advanced Hepatocellular Carcinoma(HCC).

Trial Details

NCT ID
NCT05652920
Phase
PHASE1 / PHASE2
Sponsor
OriCell Therapeutics Co., Ltd.
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Ori-C101
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Changsha, Hunan, China|28.19874,112.97087
  • Changchun, Jilin, China|43.88,125.32278
  • Chengdu, Sichuan, China|30.66667,104.06667
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Confirmed pathologic or radiologic diagnosis of HCC ;
  • Tumor tissue GPC3 expression positive by immunohistochemistry(IHC) at the local laboratory (Tumor samples ≤1 years prior to ICF signature are accep…
  • Unresectable stage B (intermediate) or C (advanced) HCC according to the Barcelona Clinic Liver Cancer (BCLC) staging. If stage B, must have progre…
  • Received at least two prior line of systemic therapy (included but not limited to target therapy, immunotherapy or chemotherapy) with radiologic di…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →